Cargando…

Radiotherapy in the management of gist: state of the art and new potential scenarios

BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatto, L., Nannini, M., Saponara, M., Di Scioscio, V., Beltramo, G., Frezza, G. P., Ercolani, G., Pinna, A. D., Astolfi, A., Urbini, M., Brandi, G., Biasco, G., Pantaleo, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223331/
https://www.ncbi.nlm.nih.gov/pubmed/28078078
http://dx.doi.org/10.1186/s13569-016-0065-z
_version_ 1782493148516188160
author Gatto, L.
Nannini, M.
Saponara, M.
Di Scioscio, V.
Beltramo, G.
Frezza, G. P.
Ercolani, G.
Pinna, A. D.
Astolfi, A.
Urbini, M.
Brandi, G.
Biasco, G.
Pantaleo, M. A.
author_facet Gatto, L.
Nannini, M.
Saponara, M.
Di Scioscio, V.
Beltramo, G.
Frezza, G. P.
Ercolani, G.
Pinna, A. D.
Astolfi, A.
Urbini, M.
Brandi, G.
Biasco, G.
Pantaleo, M. A.
author_sort Gatto, L.
collection PubMed
description BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines. CASE PRESENTATION: Here we report two patients affected by metastatic GIST, treated with radiotherapy and radiosurgery in combination with TKIs, achieving an unexpected objective response in the first case and a significant clinical benefit associated with a local tumor control of several months in the second case. CONCLUSIONS: These and other successful experiences that are progressively accumulating, open up new scenarios of use of radiation therapy in various settings of treatment. GIST is not universally radioresistant and radiotherapy, especially if combined with molecularly targeted therapy, can improve the outcomes for patients diagnosed with GIST.
format Online
Article
Text
id pubmed-5223331
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52233312017-01-11 Radiotherapy in the management of gist: state of the art and new potential scenarios Gatto, L. Nannini, M. Saponara, M. Di Scioscio, V. Beltramo, G. Frezza, G. P. Ercolani, G. Pinna, A. D. Astolfi, A. Urbini, M. Brandi, G. Biasco, G. Pantaleo, M. A. Clin Sarcoma Res Case Report BACKGROUND: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. The main treatment for localized gastrointestinal stromal tumors is surgical resection. Unresectable or advanced GIST are poorly responsive to conventional cytotoxic chemotherapy but the introduction of tyrosine kinase inhibitors (TKIs) marked a revolutionary step in the treatment of these patients, radically improving prognosis and clinical benefit. Historically GIST has been considered radiation-resistant, and the role of radiotherapy in the management of patients with GIST is currently restricted to symptomatic palliation in current treatment guidelines. CASE PRESENTATION: Here we report two patients affected by metastatic GIST, treated with radiotherapy and radiosurgery in combination with TKIs, achieving an unexpected objective response in the first case and a significant clinical benefit associated with a local tumor control of several months in the second case. CONCLUSIONS: These and other successful experiences that are progressively accumulating, open up new scenarios of use of radiation therapy in various settings of treatment. GIST is not universally radioresistant and radiotherapy, especially if combined with molecularly targeted therapy, can improve the outcomes for patients diagnosed with GIST. BioMed Central 2017-01-10 /pmc/articles/PMC5223331/ /pubmed/28078078 http://dx.doi.org/10.1186/s13569-016-0065-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Gatto, L.
Nannini, M.
Saponara, M.
Di Scioscio, V.
Beltramo, G.
Frezza, G. P.
Ercolani, G.
Pinna, A. D.
Astolfi, A.
Urbini, M.
Brandi, G.
Biasco, G.
Pantaleo, M. A.
Radiotherapy in the management of gist: state of the art and new potential scenarios
title Radiotherapy in the management of gist: state of the art and new potential scenarios
title_full Radiotherapy in the management of gist: state of the art and new potential scenarios
title_fullStr Radiotherapy in the management of gist: state of the art and new potential scenarios
title_full_unstemmed Radiotherapy in the management of gist: state of the art and new potential scenarios
title_short Radiotherapy in the management of gist: state of the art and new potential scenarios
title_sort radiotherapy in the management of gist: state of the art and new potential scenarios
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223331/
https://www.ncbi.nlm.nih.gov/pubmed/28078078
http://dx.doi.org/10.1186/s13569-016-0065-z
work_keys_str_mv AT gattol radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT nanninim radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT saponaram radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT disciosciov radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT beltramog radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT frezzagp radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT ercolanig radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT pinnaad radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT astolfia radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT urbinim radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT brandig radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT biascog radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios
AT pantaleoma radiotherapyinthemanagementofgiststateoftheartandnewpotentialscenarios